source
- AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trialAriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…
- Genetix Biotherapeutics reports $327M YTD sales and projects $500M full-year revenue, marking profitabilityGenetix Biotherapeutics, the former bluebird bio, announced that it has become profitable, reporting $327 million in U.S. net sales year‑to‑date and forecasting total 2026 sales of about $500 milli…